Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Prognostic performance of troponin in COVID-19: A diagnostic meta-analysis and meta-regression

Arief Wibowo\textsuperscript{a}, Raymond Pranata\textsuperscript{a,b}, Mohammad Rizki Akbar\textsuperscript{a}, Augustine Purnomowati\textsuperscript{a}, Januar Wibawa Martha\textsuperscript{a}\textsuperscript{,}\textsuperscript{*}

\textsuperscript{a} Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Padjadjaran, Rumah Sakit Umum Pusat Hasan Sadikin, Bandung, Indonesia
\textsuperscript{b} Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia

\textbf{ABSTRACT}

\textbf{Background:} Cardiac injury is frequently encountered in patients with coronavirus disease 2019 (COVID-19) and is associated with increased risk of mortality. Elevated troponin may signify myocardial damage and is predictive of mortality. This study aimed to assess the prognostic value of troponin above the 99th percentile upper reference limit (URL) for mortality, and factors affecting the relationship.

\textbf{Methods:} A comprehensive literature search of PubMed (MEDLINE), Scopus and Embase was undertaken, from inception of the databases until 16 December 2020. The key exposure was elevated serum troponin, defined as troponin (of any type) above the 99th percentile URL. The outcome was mortality due to any cause.

\textbf{Results:} In total, 12,262 patients from 13 studies were included in this systematic review and meta-analysis. The mortality rate was 23\% (20--26\%). Elevated troponin was observed in 31\% (23--38\%) of patients. Elevated troponin was associated with increased mortality [odds ratio (OR) 4.75, 95\% confidence interval (CI) 4.07--5.53; \( P < 0.001; \hat{P} = 19.9\%\)]. Meta-regression showed that the association did not vary with age \((P = 0.218)\), male gender \((P = 0.707)\), hypertension \((P = 0.182)\), diabetes \((P = 0.906)\) or coronary artery disease \((P = 0.0864)\). The association between elevated troponin and mortality had sensitivity of 0.55 (0.44--0.66), specificity of 0.80 (0.71--0.86), positive likelihood ratio of 2.7 (2.2--3.3), negative likelihood ratio of 0.56 (0.49--0.65), diagnosis odds ratio of 5 (4--5) and area under the curve of 0.73 (0.69--0.77). The probability of mortality was 45\% in patients with elevated troponin and 14\% in patients with non-elevated troponin.

\textbf{Conclusion:} Elevated troponin was associated with mortality in patients with COVID-19 with 55\% sensitivity and 80\% specificity.

\textcopyright 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

\begin{itemize}
  \item Background Coronavirus disease 2019 (COVID-19) has affected more than 105 million people globally and resulted in at least 2.3 million deaths (\textit{World Health Organization, 2021}). Although most patients with COVID-19 have mild symptoms or are asymptomatic, a significant proportion of patients will experience multiple complications, potentially resulting in death (\textit{Lim et al., 2020}). Biomarkers are crucial in decision-making in order to facilitate efficient resource allocation (\textit{Huang et al., 2020}).
  \item Cardiac injury is frequently encountered in patients with COVID-19 and is associated with increased risk of death (\textit{Nishiga et al., 2020; Shi et al., 2020}). Elevated troponin may signify myocardial damage and is predictive of mortality. However, the prognostic performance of troponin and whether its value is affected by various comorbidities that may be present in patients with COVID-19 are not known. This study aimed to assess the prognostic value of troponin above the 99th percentile upper reference limit (URL) for mortality, and factors affecting this relationship.
  \item Methods This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
\end{itemize}
Eligibility criteria

This study included both prospective and retrospective observational studies containing primary data on: (1) confirmed cases of COVID-19; (2) troponin with cut-off point above the 99th percentile URL; and (3) mortality rate based on the troponin cut-off point. Preprints, abstract-only publications, letters without primary data, case reports, editorials, commentaries and non-English-language articles were excluded from this study.

Search strategy and study selection

A comprehensive literature search of PubMed (MEDLINE), Scopus and Embase was undertaken using the keywords ‘covid-19’ OR ‘sars-cov-2’ OR ‘2019-ncov’ AND ‘troponin’ AND ‘mortality’ OR ‘death’ OR ‘non-survivor’ from inception of the search databases until 16 December 2020. Following the initial search, duplicates were excluded. Titles and abstracts of the identified articles were screened for eligibility by two independent authors, and the full-text of potentially eligible studies was assessed based on the inclusion and exclusion criteria.

Data extraction

Two authors extracted data independently using a form. Data of interest included first author, year of publication, sample size, study design, type of troponin, cut-off point for elevated troponin, age, sex, hypertension, diabetes, coronary artery disease and mortality rate.

The key exposure in this study was elevated serum troponin, defined as troponin (of any type) above the 99th percentile URL. The outcome was mortality, defined as clinically validated death/non-survival due to any cause.

The association between key exposure and outcome has been reported as odds ratio (OR) and 95% confidence interval (CI). To assess the prognostic value of elevated troponin, pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the curve (AUC) were calculated.

Risk-of-bias assessment

The Newcastle–Ottawa Scale (NOS) was used by two independent authors to assess the risk of bias of the included studies. Discrepancies that arose were resolved by discussion.

Statistical analysis

STATA 16 (Stata Corp, College Station, TX, USA) was used to perform the meta-analysis. Meta-analysis of proportion was performed to pool the prevalence of elevated troponin and mortality. The OR and 95% CI of the main outcome was calculated using the DerSimonian and Laird random-effects model. P < 0.05 was considered to indicate significance. Heterogeneity among the studies was assessed using the P2 and Cochran Q tests, in which a value <50% or P < 0.10, respectively, indicates significant heterogeneity. Meta-regression analysis was performed using age, gender, hypertension, diabetes and coronary artery disease as

---

**Figure 1.** PRISMA flowchart.
moderators. Funnel plot analysis, Egger’s test and Deek’s asymmetry test were used to assess the risk of publication bias and small study effects. Trim-and-fill analysis was performed to ‘normalize’ the asymmetric funnel plot. Pooled sensitivity, specificity, summary receiver operating characteristic (SROC) curve, Fagan’s nomogram and Deek’s asymmetry plot were generated.

### Results

In total, this systematic review and meta-analysis included 12,262 patients from 13 studies (Figure 1) (Al Abbasi et al., 2020; Arcari et al., 2020; Connor-Schuler et al., 2020; Du et al., 2020; Heron and Chiu, 2020; Li et al., 2020; Lombardi et al., 2020; Maeda et al., 2020; Raad et al., 2020; Shah et al., 2020; Harmouch et al.,

![Figure 2](image_url)

**Figure 2.** Elevated troponin and mortality. (A) Forest plot. (B) Funnel plot. (C) Trim-and-fill analysis. CI, confidence interval.
The mortality rate was 23% (20–26%). Thirty-one percent (23–38%) of patients had elevated troponin. The risk-of-bias assessment using the NOS indicates low–moderate risk of bias.

Elevated troponin and mortality

Elevated troponin was associated with increased mortality [OR 4.75 (95% CI 4.07–5.53), P < 0.001; I² = 19.9%, P = 0.242] (Figure 2). Meta-regression showed that the association did not vary with age (P = 0.218), male gender (P = 0.707), hypertension (P = 0.182), diabetes (P = 0.906) or coronary artery disease (P = 0.864). Egger’s test showed no indication of a small study effect (P = 0.536). The funnel plot was asymmetric (Figure 2B). Trim-and-fill analysis by imputation of two studies resulted in OR of 4.52 (95% CI 3.82–5.36) (Figure 2C).

Prognostic value

The association between elevated troponin and mortality had sensitivity of 0.55 (0.44–0.66), specificity of 0.80 (0.71–0.86) (Figure 3), PLR of 2.7 (2.2–3.3), NLR of 0.56 (0.49–0.65), DOR of 5 (4–5) and AUC of 0.73 (0.69–0.77) (Figure 4). Fagan’s nomogram indicated that elevated troponin resulted in 45% post-test probability of mortality, and non-elevated troponin resulted in 14% post-test probability of mortality (Figure 5). Deek’s funnel plot indicated symmetry with respect to the regression line, and the quantitative plot asymmetry test was not significant (P = 0.86) (Figure 6). Univariate meta-regression and subgroup analyses indicated that age, male gender, hypertension and diabetes did not significantly affect pooled sensitivity or specificity (Figure 7).

Discussion

Elevated troponin was associated with an almost five-fold increase in mortality compared with patients without elevated troponin, with 55% sensitivity and 80% specificity. Meta-regression indicated that the association between elevated troponin and mortality did not vary with age, male gender, hypertension, diabetes or coronary artery disease, indicating that
although some of the abovementioned factors are associated with mortality, myocardial damage/dysfunction (Zethelius et al., 2006; Pattanshetty et al., 2012; McEvoy et al., 2015; Segre et al., 2015; Cavender et al., 2017; Whelton et al., 2017; Lombardi et al., 2020) and mortality in patients with COVID-19 (Huang et al., 2020; Pranata et al., 2020c,d,g), these factors did not modify the troponin–mortality relationship. However, other crucial variables such as chronic kidney disease and chronic obstructive pulmonary disease cannot be assessed because they were not reported in most of the studies (Pranata et al., 2020e,f).

Elevated troponin was associated with 80% specificity and 45% chance of mortality with 23% pre-test probability of mortality. However, it had low sensitivity (50%), so elevated troponin is best used for ruling in the risk of mortality rather than ruling it out. The funnel plot was slightly asymmetric, indicating possible publication bias; a trim-and-fill analysis was performed which slightly reduced the effect estimate. Thus, it is improbable that publication bias has altered the positive association between elevated troponin and mortality. Furthermore, Egger’s test and Deek’s asymmetry test did not detect possible publication bias. The pooled effect estimate had low heterogeneity, indicating consistency despite different types of troponin and populations. This low heterogeneity is likely due to the use of a cut-off point above the 99th percentile URL instead of a specific cut-off point, as the result was less likely to be altered by laboratory reference values and calibrations.

Cardiac injury is frequently encountered in patients with COVID-19. Although the mechanism is only vaguely understood, the interaction between the S protein and angiotensin-converting enzyme 2 is likely to be essential (Nishiga et al., 2020; Shi et al., 2020). In addition to cardiac injury, COVID-19 may also cause arrhythmia, myocardial ischaemia and thromboembolism (Pranata et al., 2020e,f).

Figure 5. Fagan’s nomogram. LR, likelihood ratio.
et al., 2020b). Other cardiac biomarkers, such as natriuretic peptide, are often elevated in patients with COVID-19 and signify poor prognosis (Pranata et al., 2020a).

Additionally, echocardiographic parameters such as global longitudinal strain, right ventricular strain and tricuspid annular plane systolic excursion have been shown to be valuable tools in patients with COVID-19 (Martha et al., 2021; Wibowo et al., 2021). These parameters may signify cardiac injury and right ventricular performance, which may be affected by ongoing lung pathologies in patients with COVID-19.

**Clinical implications**

This meta-analysis found that troponin above the 99th percentile URL increases mortality five-fold with 55% sensitivity and 80% specificity. It has a PLR of 2.7, NLR of 0.56 and AUC of 0.73. However, sensitivity is low. To enhance performance, echocardiographic and laboratory parameters such as natriuretic peptides need to be integrated into the prognostic model. This may result in greater sensitivity and specificity, which may increase its clinical usefulness.

**Limitations**

The main limitation of this review is that most studies were retrospective. Additionally, a significant proportion of the studies did not report crucial variables such as chronic kidney disease, chronic obstructive pulmonary disease and heart failure; thus, these variables could not be included in the meta-regression.
Nevertheless, the low heterogeneity means that, despite variation in these comorbidities, the association between elevated troponin and mortality was consistent.

Conclusion

Elevated troponin was associated with mortality with 55% sensitivity and 80% specificity. The association did not vary by age, male gender, hypertension, diabetes or coronary artery disease.

Conflict of interest

None.

Funding

None.

Ethical approval

Not required.

CRediT authorship contribution statement

Arief Wirbowo: Conceptualization, Data curation, Investigation, Writing - original draft, Writing - review & editing. Raymond Pranata: Conceptualization, Methodology, Software, Data curation, Formal analysis, Investigation, Validation, Writing - original draft, Writing - review & editing. Mohammad Rizki Akbar: Conceptualization, Investigation, Writing - original draft, Supervision. Augustine Purnomowianti: Investigation, Writing - review & editing. Januar Wibawa Martha: Investigation, Writing - review & editing.

References

Al Abbasi B, Torres P, Ramos-Tuarez F, Dewaswala N, Abdallah A, Chen K, et al. Cardiac troponin-I and COVID-19: a prognostic tool for in-hospital mortality. Cardiol Res 2020;11:398–404.

Arcari L, Luciani M, Cacciotti L, Musumeci MB, Spuntarelli V, Pistella E, et al. Incidence and determinants of high-sensitivity troponin and natriuretic peptides elevation at admission in hospitalized COVID-19 pneumonia patients. Intern Emerg Med 2020;15:1467–76.

Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kuper S, et al. Serial measurement of high-sensitivity troponin I and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE trial (Examination of Cardiovascular Outcomes with Allopurinol Versus Standard of Care). Circulation 2017;135:1911–21.

Connor-Schuler R, Wong AL, Shah A, Fiza B, Lyle M, Ramonell R, et al. Experience with cardiology-outcome oriented results in critically ill patients with coronavirus disease 2019. Crit Care Explor 2020;2:e0288.

Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J 2020;55:2000524.

Harmouch F, Shah K, Hippen JT, Kumar A, Goel H. Is it all in the heart? Myocardial injury as major predictor of mortality among hospitalized COVID-19 patients. J Med Virol 2021;93:973–82.

Heron RC, Chiu WW. Hydroxy-chloroquine interference in common biochemistry laboratory assays. J Appl Lab Med 2020;5:1130–7.

Huang L, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – a systematic review, meta-analysis, and meta-regression: diabetes and COVID-19. Diabetes Metab Syndr Clin Res Rev 2020;14:395–403.

Li C, Jiang J, Wang F, Zhou N, Veronese C, Mosleh JJ, et al. Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients. J Mol Cell Cardiol 2020;147:74–87.

Lim MA, Pranata R, Huang I, Yonas E, Soeroto AY, Supriyadi R. Multiorgan failure with emphasis on acute kidney injury and severity of COVID-19: systematic review and meta-analysis. Can J Rural Health Dis 2020;7:2054588120938573.

Lombardi CM, Carubelli V, Iovio A, Inciardi RM, Bellasi A, Canale C, et al. Association of troponin levels with mortality in Italian patients hospitalized with coronavirus disease 2019: results of a multicenter study. JAMA Cardiol 2020;5:1274–80.

Maeda T, Obata R, Rizk D, Kuno T. Cardiac injury and outcomes of patients with COVID-19 in New York City. Hear Lung Circ 2020; doi: http://dx.doi.org/10.1016/j.hlc.2020.10.025.

Majure DT, Gruberg L, Saba SG, Kusnavsky C, Hirsch JS, Jauhar R. Usefulness of elevated troponin to predict death in patients with COVID-19 and myocardial injury. Am J Cardiol 2021;138:100–6.

Martha JW, Pranata R, Wirbowo A, Lim MA. Tricuspid annular plane systolic excursion (TAPSE) measured by echocardiography and mortality in COVID-19: a systematic review and meta-analysis. Int J Infect Dis 2021;1:1–8.

Mcevoy JW, Chen Y, Nambi V, Ballantyne CM, Sharrett AR, Appel LJ, et al. High-sensitivity cardiac troponin T and risk of hypertension. Circulation 2015;132:825–33.

Metkus TS, Sokoll LJ, Barth AS, Czarny MJ, Hays AG, Lowenstein CJ, et al. Myocardial injury in severe COVID-19 compared to non-COVID acute respiratory distress syndrome. Circulation 2021;143:553–65.

Nishiga M, Wang DW, Han Y, Lewis DB, Wu J. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol 2020;17:543–58.

Partanshetty DJ, Bhat PK, Anjela A, Pillai DP. Elevated troponin predicts long-term adverse cardiovascular outcomes in hypertensive crisis: a retrospective study. J Hypertens 2012;30:2410–5.

Pranata R, Huang I, Lukito AA, Raharjo SB. Elevated N-terminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19: systematic review and meta-analysis. Postgrad Med J 2020a;96:387–91.

Pranata R, Huang I, Raharjo SB. Incidence and impact of cardiac arrhythmias in coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Indian Pacifying Endocrinol J 2020b;20:193–5.

Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin-Angiotensin Aldosterone Syst 2020c;21:1470520320926899.

Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin-Angiotensin Aldosterone Syst 2020d;21:1470520320926899.

Pranata R, Soeroto AY, Huang I, Lim MA, Santoso P, Permama H, et al. Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19. Int J Tuberc Lung Dis 2020e;24:838–43.

Pranata R, Supriyadi R, Huang I, Permama H, Lim MA, Yonas E, et al. The association between chronic kidney disease and new onset renal replacement therapy on the outcome of COVID-19 patients: a meta-analysis. Clin Med Insights Circ Respirol Pulm Med 2020f;14:177958420959165.

Pranata R, Lim MA, Yonas E, Viaia R, Lukito AA, Siswanto BB, et al. Body mass index and outcome in patients with COVID-19: a dose–response meta-analysis. Diabetes Metab 2020g;47(2):101178.

Raad M, Dabbagh M, Gorgis S, Yan J, Chehab O, Dagher C, et al. Cardiac injury markers and inpatient outcomes among patients admitted with COVID-19. Am J Cardiol 2020;113:154–61.

Segre CAW, Hueb W, Garcia RMR, Rezende PC, Favaro D, Strunz CMC, et al. Troponin in diabetic patients with and without chronic coronary artery disease. BMC Cardiovasc Disord 2015;15:72.

Shah P, Doshi R, Chenna A, Owens R, Cobb A, Ivey H, et al. Prognostic value of elevated cardiac troponin I in hospitalized COVID-19 patients. Am J Cardiol 2020;135:150–3.

Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020;5:802–10.

Whelton SP, McEvoy LW, Lazo M, Coresh J, Bailtanyme CM, Selvin E. High-sensitivity cardiac troponin T (hs-CtT) as a predictor of incident diabetes in the atherosclerosis risk in communities study. Diabetes Care 2017;40:261–9.

Wirbowo A, Pranata R, Astuti A, Tiksnadi BB, Martanto E, Martha JW, et al. Left and right ventricular longitudinal strains are associated with poor outcome in COVID-19: a systematic review and meta-analysis. J Intensive Care 2021;9:9.

World Health Organization. Weekly epidemiological update – 9 February 2021. Geneva: WHO; 2021.

Zethelius B, Johnston N, Venge P. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Circulation 2006;113:1071–8.